Cofactor-specific modulation of 11β-hydroxysteroid dehydrogenase 1 inhibitor potency

• Published in: Biochimica et biophysica acta. Proteins and proteomics 2007-09, Vol.1774 (9), p.1184-1191
• Main Authors: Sahni-Arya, Bhavana, Flynn, Michael J., Bergeron, Laurie, Salyan, Mary Ellen K., Pedicord, Donna L., Golla, Rajasree, Ma, Zhengping, Wang, Haixia, Seethala, Ramakrishna, Wu, Shung C., Li, James J., Nayeem, Akbar, Gates, Cynthia, Hamann, Lawrence G., Gordon, David A., Blat, Yuval
• Format: Article
• Language: English
• Subjects: 11β-HSD1; Glucocorticoid; Inhibitor
• ISSN: 1570-9639; 1878-1454
• DOI: 10.1016/j.bbapap.2007.07.005

11β-hydroxysteroid dehydrogenase 1 regulates the tissue availability of cortisol by interconverting cortisone and cortisol. It is capable of functioning as both a reductase and a dehydrogenase depending upon the surrounding milieu. In this work, we have studied the reaction mechanism of a soluble form of human 11β-hydroxysteroid dehydrogenase 1 and its mode of inhibition by potent and selective inhibitors belonging to three different structural classes. We found that catalysis follows an ordered addition with NADP(H) binding preceding the binding of the steroid. While all three inhibitors tested bound to the steroid binding pocket, they differed in their interactions with the cofactor NADP(H). Compound A, a pyridyl amide bound more efficiently to the NADPH-bound form of 11β-hydroxysteroid dehydrogenase 1. Compound B, an adamantyl triazole, was unaffected by NADP(H) binding and the sulfonamide, Compound C, showed preferential binding to the NADP +-bound form of 11β-hydroxysteroid dehydrogenase 1. These differences were found to augment significant selectivity towards inhibition of the reductase reaction versus the dehydrogenase reaction. This selectivity may translate to differences in the in vivo effects of 11β-hydroxysteroid dehydrogenase 1 inhibitors.